# Reed Siemieniuk

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/reed-siemieniuk/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,692 |
| Field | Meta-analysis and systematic reviews |
| h-index | 68 |
| i10-index | 118 |
| Last Known Institution | Impact |
| OpenAlex ID | https://openalex.org/A5072226388 |
| ORCID iD | https://orcid.org/0000-0002-3725-3031 |
| Works | 168 |

## Researcher papers

- [A living WHO guideline on drugs for covid-19 (2020-2023)](https://scholariq.org/papers/a-living-who-guideline-on-drugs-for-covid-19-2020-2023/)
- [Drug treatments for covid-19: living systematic review and network meta-analysis](https://scholariq.org/papers/drug-treatments-for-covid-19-living-systematic-review-and-network-meta-analysis/)
- [Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis](https://scholariq.org/papers/advances-in-the-grade-approach-to-rate-the-certainty-in-estimates-from-a-network/)
- [Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults](https://scholariq.org/papers/comparison-of-weight-loss-among-named-diet-programs-in-overweight-and-obese/)
- [Living systematic review: 1. Introduction—the why, what, when, and how](https://scholariq.org/papers/living-systematic-review-1-introduction-the-why-what-when-and-how/)
- [GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks](https://scholariq.org/papers/grade-guidelines-28-use-of-grade-for-the-assessment-of-evidence-about-prognostic/)
- [Living systematic reviews: 2. Combining human and machine effort](https://scholariq.org/papers/living-systematic-reviews-2-combining-human-and-machine-effort/)
- [Living systematic reviews: 4. Living guideline recommendations](https://scholariq.org/papers/living-systematic-reviews-4-living-guideline-recommendations/)
- [Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials](https://scholariq.org/papers/benefits-and-harms-of-drug-treatment-for-type-2-diabetes-systematic-review-and/)
- [Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: instrument development and reliability study](https://scholariq.org/papers/evaluating-the-credibility-of-anchor-based-estimates-of-minimal-important/)
- [Development of the summary of findings table for network meta-analysis](https://scholariq.org/papers/development-of-the-summary-of-findings-table-for-network-meta-analysis/)
- [Living systematic reviews: 3. Statistical methods for updating meta-analyses](https://scholariq.org/papers/living-systematic-reviews-3-statistical-methods-for-updating-meta-analyses/)

## Researcher topics

- [Meta-analysis and systematic reviews](https://scholariq.org/topics/meta-analysis-and-systematic-reviews/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [HIV/AIDS Research and Interventions](https://scholariq.org/topics/hiv-aids-research-and-interventions/)
- [Sepsis Diagnosis and Treatment](https://scholariq.org/topics/sepsis-diagnosis-and-treatment/)
- [HIV/AIDS drug development and treatment](https://scholariq.org/topics/hiv-aids-drug-development-and-treatment/)

## Researcher university

- [Impact](https://scholariq.org/institutions/impact/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.